

Johannes BrÄngelmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3020769/publications.pdf>

Version: 2024-02-01

44
papers

2,835
citations

304743

22
h-index

265206

42
g-index

45
all docs

45
docs citations

45
times ranked

5996
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641.	7.0	525
2	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. <i>Cancer Cell</i> , 2017, 31, 270-285.	16.8	406
3	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. <i>Clinical Cancer Research</i> , 2015, 21, 870-881.	7.0	303
4	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	1.1	178
5	FirebrowserR: an R client to the Broad Institute's Firehose Pipeline. <i>Database: the Journal of Biological Databases and Curation</i> , 2017, 2017, baw160.	3.0	144
6	Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. <i>BMC Bioinformatics</i> , 2016, 17, 72.	2.6	140
7	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
8	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 52889-52900.	1.8	82
9	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011, 12, 9-46.	3.4	79
10	Family matters: How MYC family oncogenes impact small cell lung cancer. <i>Cell Cycle</i> , 2017, 16, 1489-1498.	2.6	75
11	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1829-1840.	7.0	74
12	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1337-1343.	7.0	71
13	Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 932-939.	1.8	57
14	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	55
15	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 3485.	12.8	54
16	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 632-644.	7.0	49
17	Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	7.0	44
18	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. <i>Cell Reports</i> , 2017, 20, 2833-2845.	6.4	40

#	ARTICLE	IF	CITATIONS
19	Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 7.	4.1	36
20	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	12.8	30
21	Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. <i>International Journal of Cancer</i> , 2016, 139, 2359-2369.	5.1	27
22	Rare occurrence of EGFRVIII deletion in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 53-58.	1.5	26
23	Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer. <i>Hepatology</i> , 2021, 73, 2293-2310.	7.3	24
24	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. <i>Oncotarget</i> , 2016, 7, 23043-23055.	1.8	24
25	Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 577-588.	5.1	23
26	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 14719-14735.	1.8	21
27	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
28	MERTK as a novel therapeutic target in head and neck cancer. <i>Oncotarget</i> , 2016, 7, 32678-32694.	1.8	17
29	A comparative analysis of cell-type adjustment methods for epigenome-wide association studies based on simulated and real data sets. <i>Briefings in Bioinformatics</i> , 2019, 20, 2055-2065.	6.5	15
30	Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. <i>International Journal of Cardiology</i> , 2014, 177, 830-835.	1.7	14
31	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. <i>Frontiers in Medicine</i> , 2017, 4, 30.	2.6	13
32	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. <i>Diagnostic Pathology</i> , 2015, 10, 165.	2.0	11
33	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	5.4	11
34	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. <i>Targeted Oncology</i> , 2016, 11, 631-642.	3.6	10
35	CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5508.	4.1	6
36	Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT. <i>Cancers</i> , 2022, 14, 1894.	3.7	6

#	ARTICLE	IF	CITATIONS
37	Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. <i>American Journal of Pathology</i> , 2022, 192, 813-823.	3.8	4
38	CD74-NRG1 Fusions Are Oncogenic <i>In Vivo</i> and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 821-830.	4.1	4
39	Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 255-256.	1.7	3
40	CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. <i>Human Pathology</i> , 2021, 117, 60-67.	2.0	3
41	Normics: Proteomic Normalization by Variance and Data-Inherent Correlation Structure. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100269.	3.8	2
42	Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on TP53 mutated, as well as oral cavity cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6080-6080.	1.6	0
43	Abstract 1920: Targeting structural RET and MET kinase alterations in lung adenocarcinoma patients. , 2018, , .		0
44	Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC. , 2018, , .		0